---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002268"
form_type: "8-K"
ticker: null
cik: "0001641640"
company_name: "Nabriva Therapeutics plc"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:54:04.063367+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Nabriva Therapeutics adopts Cash Preservation Plan to wind down operations, terminates most employees

## Summary
- Board approved plan on Jan 4, 2023 to preserve cash for an orderly wind down; all employees not needed for wind-down terminated.
- Repaid $4.5M to Hercules Capital under Loan Agreement, terminating the facility and releasing all security interests.
- Estimates ~$6.0M in severance and termination costs in Q1 2023; workforce reduction substantially complete by end of Q1.
- Terminated Amplity Health sales force; will transition SIVEXTRO promotion back to Merck & Co. over coming months.
- Company exploring sale of assets including Lefamulin and IV Fosfomycin; may seek shareholder approval for liquidation/dissolution.

## SEC filing metadata
- accession: 0001104659-23-002268
- form_type: 8-K
- cik: 0001641640
- company_name: Nabriva Therapeutics plc
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.02, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641640/000110465923002268/0001104659-23-002268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641640/000110465923002268/tm232720d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002268
- JSON: https://secwatch.observer/filing/0001104659-23-002268.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002268.txt

## Key facts
- Material Agreements
  Nabriva Therapeutics plc terminated Loan Agreement with Hercules Capital, Inc. valued at $4.5 million (effective 2023-01-05).
  - Action: termination
  - Agreement: credit facility
  - Counterparty: Hercules Capital, Inc.
  - Value: $4.5 million
  - Effective: 2023-01-05
  source text: On January 5, 2023, the Company, in connection with the Cash Preservation Plan, repaid in full all outstanding amounts owed under the Loan and Security Agreement, dated as of December 20, 2018, by and among the Company, Nabriva Therapeutics Ireland Designated Activity Company, certain other subsidiaries of the Company from time to time party thereto, any bank and other financial institution or entity from time to time party thereto and Hercules Capital, Inc. (“Hercules”), as administrative agent and collateral agent. (as supplemented, amended or otherwise modified from time to time, the “Loan Agreement”). The Company’s total repayment to Hercules under the Loan Agreement was $4.5 million, including a principal, accrued and unpaid interest, fees and other expenses. Effective at the time of the repayment, the Loan Agreement was terminated, and Hercules released all security interests held on the assets of the Company and its subsidiaries.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641640/000110465923002268/0001104659-23-002268-index.htm
- Restructurings & Charges
  Nabriva Therapeutics plc announced a restructuring with charges of Termination of all employees not deemed necessary to execute an orderly wind down of the Company affecting Workforce (all of its employees not deemed necessary to execute an orderly wind down of the Company).
  - Type: restructuring
  - Charge: Termination of all employees not deemed necessary to execute an orderly wind down of the Company
  - Affected area: Workforce
  - Headcount: all of its employees not deemed necessary to execute an orderly wind down of the Company
  source text: As part of the Cash Preservation Plan, the Board determined on January 4, 2023 to terminate all of its employees not deemed necessary to execute an orderly wind down of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641640/000110465923002268/0001104659-23-002268-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.